Short Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Declines By 87.7%

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a significant drop in short interest during the month of June. As of June 15th, there was short interest totaling 1,503 shares, a drop of 87.7% from the May 31st total of 12,174 shares. Based on an average daily volume of 6,655 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the company’s stock are sold short.

Santen Pharmaceutical Trading Down 1.2%

SNPHY traded down $0.15 during trading on Friday, reaching $12.95. 234 shares of the company were exchanged, compared to its average volume of 12,429. Santen Pharmaceutical has a 52 week low of $9.22 and a 52 week high of $13.10. The firm has a 50 day moving average of $11.53 and a 200 day moving average of $11.12. The stock has a market cap of $4.17 billion and a P/E ratio of 0.10.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company currently has an average rating of “Hold”.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan?based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over?the?counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post?operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.